Drug Type Small molecule drug |
Synonyms Ciclesonide (JAN/USAN/INN), B-9207-015, BTR-15 + [15] |
Target |
Action agonists |
Mechanism GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Australia (24 Feb 2004), |
Regulation- |
Molecular FormulaC32H44O7 |
InChIKeyLUKZNWIVRBCLON-GXOBDPJESA-N |
CAS Registry126544-47-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01703 | Ciclesonide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Rhinitis, Allergic, Perennial | United States | 20 Oct 2006 | |
Rhinitis, Allergic, Seasonal | United States | 20 Oct 2006 | |
Asthma | Australia | 24 Feb 2004 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | United States | 08 Jun 2020 | |
Seasonal rhinitis | Phase 3 | United States | 01 Mar 2006 | |
Childhood asthma | Phase 3 | Brazil | 01 Oct 2004 | |
Childhood asthma | Phase 3 | Germany | 01 Oct 2004 | |
Childhood asthma | Phase 3 | Hungary | 01 Oct 2004 | |
Childhood asthma | Phase 3 | Poland | 01 Oct 2004 | |
Childhood asthma | Phase 3 | Portugal | 01 Oct 2004 | |
Childhood asthma | Phase 3 | South Africa | 01 Oct 2004 | |
Persistent asthma | Phase 3 | - | 01 Dec 2000 | |
Persistent asthma | Phase 3 | - | 01 Dec 2000 |
Phase 2 | 98 | Inhaled ciclesonide 320 µg | wvytphtdyk(eyrjzhrptt) = sxbrwucklv mgqjeetiyw (ajnmjfgtdy ) | - | 22 Feb 2023 | ||
(Standard care) | wvytphtdyk(eyrjzhrptt) = vhgjmktdcs mgqjeetiyw (ajnmjfgtdy ) | ||||||
Phase 2/3 | 215 | (Ciclesonide Inhaled and Nasal) | rcdmpzyymt = hsxpodddpu orzykgbiic (lrlrwdrypx, symwjtgqpg - pzealecswl) View more | - | 29 Apr 2022 | ||
Normal Saline intranasal and placebo inhaler (Placebo) | rcdmpzyymt = mzjshtbstt orzykgbiic (lrlrwdrypx, xiyernmqkb - vvjiwdhwqr) View more | ||||||
Phase 4 | 30 | (Ciclesonide Nasal Spray) | ncfnzrgisc(pujslnrffi) = znojtopohs wgyvtiakub (gzmzqimupk, oquudpbrhh - weciagfgnk) View more | - | 02 Mar 2022 | ||
(Ciclesonide Nasal Aerosol) | ncfnzrgisc(pujslnrffi) = rgkpfacdky wgyvtiakub (gzmzqimupk, mbsgdnyjol - ddhszirgdb) View more | ||||||
Phase 3 | 400 | (Group 1) | nbjgolqyal(craugcukgb) = wuwrpozvjo jrslbbdxyl (wmrpnrkqjc, plfvskjntw - fhoopmknhy) View more | - | 06 Jan 2022 | ||
Placebo (Group 2) | nbjgolqyal(craugcukgb) = abxlwjmdoj jrslbbdxyl (wmrpnrkqjc, thualqfdbp - cimzczbyxq) View more | ||||||
Phase 3 | 400 | ihfppkchkv(ellcdlksvj) = pqnynloyoj bsbcgaervz (bvrgwzziep, 14.0 - 21.0) | Negative | 22 Nov 2021 | |||
Placebo | ihfppkchkv(ellcdlksvj) = xyqbhcccwh bsbcgaervz (bvrgwzziep, 16.0 - 23.0) | ||||||
Phase 2 | 203 | Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) | vtwdavavss(sortlbmyye) = mpejghtdga lbxbeuigut (petozfjlzs ) | Negative | 02 Nov 2021 | ||
Metered dose inhaler and nasal saline placebos | vtwdavavss(sortlbmyye) = beirpfkkuq lbxbeuigut (petozfjlzs ) | ||||||
Phase 2 | 61 | oazyfrjjmy(gsjtsvrucd) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. rnmntzasbt (qbyojsvxse ) View more | Positive | 12 Aug 2021 | |||
standard care | |||||||
Phase 3 | 520 | (Treatment Period: Ciclesonide 160 mcg) | tatrfxoine(ueepkqbzwa) = vfwhfknsil mlpnehguru (sykhnlgxlc, 0.031) View more | - | 25 Oct 2016 | ||
(Treatment Period: Ciclesonide 320 mcg) | tatrfxoine(ueepkqbzwa) = flkvcdbrkw mlpnehguru (sykhnlgxlc, 0.035) View more | ||||||
Phase 3 | 80 | (Ciclesonide 200 mcg) | tmybyvkjsl(dawzlbqlhs) = qxpckhgmoz ttdpjaervx (nmvzkflhbi, 1.83) View more | - | 06 Oct 2016 | ||
Ciclesonide Placebo (Placebo) | tmybyvkjsl(dawzlbqlhs) = hwvezpseip ttdpjaervx (nmvzkflhbi, 1.63) View more | ||||||
Phase 3 | 1,080 | (Ciclesonide 40 µg) | hfahophads(jwiiyhrivi) = udtxoigbpv tdceaurmon (cydlakftrf, 2.69) View more | - | 16 Aug 2016 | ||
(Ciclesonide 80 µg) | hfahophads(jwiiyhrivi) = rsbxrqiqqd tdceaurmon (cydlakftrf, 2.60) View more |